Pseudomyxoma Peritonei: A rare type of cancer where mucous-producing cancer cells in the abdomen produce excessive mucous. More detailed information about the symptoms, causes, and treatments of Pseudomyxoma Peritonei is available below.
Read more about complications of Pseudomyxoma Peritonei.
Research the causes of these diseases that are similar to, or related to, Pseudomyxoma Peritonei:
Unusual case of Pseudomyxoma peritonei: Pseudomyxoma peritonei is a locally malignant unusual disease commonly seen in females which is caused by a low -grade mucinous cystadenocarcinoma of the appendix or ovary that secretes large amounts of mucus containing epithelial cells. In most cases the site of origin is the appendix with secondary implantation in one or both the ovaries. In this condition there is diffuse collection of gelatinous fluid in the peritoneal cavity associated with mucinous implants on the surface of the peritoneum and omentum.There is no lymph node or extraperitoneal metastasis. Psudomyxoma is often asymptomatic until very late in its course with the patient often experiencing overall deterioration of health long before the diagnosis is made. The symptoms are non specific and include abdominal pain and abdominal distention. Occasionally a palpable mass may be present. It is usually confused with loculated ascites and ovarian carcinoma. It can be investigated using US and CT scan. The treatment consists of thorough surgical debulking along with adjuvant intraperitoneal chemotherapy. Appendicectomy is routinely performed along with Bilateral salpingo-oopherectomy in females....read more »
Read more about Misdiagnosis and Pseudomyxoma Peritonei
Medical research articles related to Pseudomyxoma Peritonei include:
Click here to find more evidence-based articles on the TRIP Database
Whenever you go to a hospital or clinic for a major procedure or diagnostic test, one of the many forms you are given to sign is an "informed...
Stress takes its toll by making us anxious, depressed and not able to function as fully as we'd like. What many don't know is that stress can...
Health insurance is important to everyone, especially people with chronic conditions like Crohn's disease and ulcerative colitis. Tune in to...
Sleep is necessary to feel refreshed, but now we know sleep actually impacts the way the body functions. Sleeping poorly can affect how often you get...
Visit our research pages for current research about Pseudomyxoma Peritonei treatments.
The US based website ClinicalTrials.gov lists information on both federally and privately supported clinical trials using human volunteers.
Some of the clinical trials listed on ClinicalTrials.gov for Pseudomyxoma Peritonei include:
See full list of 12 Clinical Trials for Pseudomyxoma Peritonei
Read about other experiences, ask a question about Pseudomyxoma Peritonei, or answer someone else's question, on our message boards:
Pseudomyxoma Peritonei is listed as a "rare disease" by the Office of
Rare Diseases (ORD) of the National Institutes of Health
(NIH). This means that Pseudomyxoma Peritonei, or a subtype of Pseudomyxoma Peritonei,
affects less than 200,000 people in the US population.
Source - National Institutes of Health (NIH)
Ophanet, a consortium of European partners,
currently defines a condition rare when it affects 1 person per 2,000.
They list Pseudomyxoma Peritonei as a "rare disease".
Source - Orphanet
» Next page: What is Pseudomyxoma Peritonei?
What do you think about the features of this website? Take our user survey and have your say:
Next articles:
Tools & Services:
Medical Articles:
Search Specialists by State and City
By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.
Copyright © 2009 Health Grades Inc. All rights reserved.
